Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
IL33 (MIM 608678) is a member of the IL1 (see MIM 147760) family that potently drives production of T helper-2 (Th2)-associated cytokines (e.g., IL4; MIM 147780). Additionally we are shipping Interleukin 33 Proteins (110) and Interleukin 33 Kits (62) and many more products for this protein.
Showing 10 out of 369 products:
Mouse (Murine) Polyclonal Interleukin 33 Primary Antibody for FACS - ABIN2661329
Arend, Palmer, Gabay: IL-1, IL-18, and IL-33 families of cytokines. in Immunological reviews 2008
Show all 5 references for ABIN2661329
Human Polyclonal Interleukin 33 Primary Antibody for EIA, WB - ABIN500014
Dinarello: Interleukin-18, a proinflammatory cytokine. in European cytokine network 2000
Show all 4 references for ABIN500014
Mouse (Murine) Polyclonal Interleukin 33 Primary Antibody for IF, IP - ABIN2665498
Moussion, Ortega, Girard: The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? in PLoS ONE 2008
Show all 4 references for ABIN2665498
Human Polyclonal Interleukin 33 Primary Antibody for EIA, IF - ABIN500012
Brint, Xu, Liu, Dunne, McKenzie, ONeill, Liew: ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. in Nature immunology 2004
Show all 4 references for ABIN500012
Human Monoclonal Interleukin 33 Primary Antibody for Func, IP - ABIN1169172
Pace, Di Sano, Sciarrino, Scafidi, Ferraro, Chiappara, Siena, Gangemi, Vitulo, Giarratano, Gjomarkaj: Cigarette smoke alters IL-33 expression and release in airway epithelial cells. in Biochimica et biophysica acta 2014
Show all 4 references for ABIN1169172
Human Polyclonal Interleukin 33 Primary Antibody for EIA, WB - ABIN401104
Hayakawa, Hayakawa, Matsuyama, Tamemoto, Okazaki, Tominaga: Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. in Biochemical and biophysical research communications 2009
Show all 4 references for ABIN401104
Human Polyclonal Interleukin 33 Primary Antibody for FACS - ABIN2661328
McLaren, Michael, Salter, Ashlin, Calder, Miller, Liew, Ramji: IL-33 reduces macrophage foam cell formation. in Journal of immunology (Baltimore, Md. : 1950) 2010
Show all 3 references for ABIN2661328
Human Monoclonal Interleukin 33 Primary Antibody for EIA, WB - ABIN317536
Baekkevold, Roussigné, Yamanaka, Johansen, Jahnsen, Amalric, Brandtzaeg, Erard, Haraldsen, Girard: Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. in The American journal of pathology 2003
Human Polyclonal Interleukin 33 Primary Antibody for IHC, WB - ABIN2784443
Humphreys, Xu, Hepworth, Liew, Grencis: IL-33, a potent inducer of adaptive immunity to intestinal nematodes. in Journal of immunology (Baltimore, Md. : 1950) 2008
in breast tumors from 40 female patients with absent or present tumor necrosis there was significantly higher expression of IL-33, IL-33R and VEGF in breast cancer tissues with absent tumor necrosis. Both, IL-33 and IL-33R expression correlated with VEGF expression in tumor cells.
Data suggest that interleukin 33 (IL-33) may play an important role in the development of non-small cell lung cancer (NSCLC) and the targeted therapy.
rs7044343 polymorphism of IL-33 gene is associated with the susceptibility to systemic sclerosis in Turkish population.
In mild untreated asthma, the expression of IL-33 mRNA in bronchial mucosa is related to innate immune activation and allergic sensitization to HDM (show HDAC3 Antibodies), rather than epithelial damage, and correlates with FeNO.
Serum IL-33 levels are suppressed in Sjogren syndrome patients.
Increased induction and expression of TSLP (show TSLP Antibodies), IL-25 (show IL25 Antibodies), and IL-33 from nasal epithelial cells contribute to the pathophysiology of eosinophilic chronic rhinosinusitis.
Serum IL-33 level is increased in children with ulcerative colitis as compared with control. Serum level correlated with the disease activity.
IL-33-ERK (show EPHB2 Antibodies)/JNK (show MAPK8 Antibodies)/p38 (show CRK Antibodies)/Egr-1 (show EGR1 Antibodies)/TSLP (show TSLP Antibodies) axis involved in allergic skin Th2 inflammation
data suggest that IL-33/ST2 (show SULT2A1 Antibodies) axis closely associates with poor prognosis of EOC patients, and it promotes ovarian cancer growth and metastasis through regulating ERK (show EPHB2 Antibodies) and JNK (show MAPK8 Antibodies) signaling pathways
Our findings indicate that the alarmin cytokines IL-33 and IL-25 (show IL25 Antibodies) increase basophil activation and migratory potential, and may pose as a novel therapeutic targets for the treatment of allergic asthma.
anti-allergic effect of anti-IL-33 antibodies associated with suppression of immunoglobulin free light chain and nitric oxide synthase (show NOS Antibodies) in a murine model of allergic rhinitis
Data suggest that IL-33 and ST2 function as a developmental switch to license thermogenesis during the perinatal period.
some SNPs of ST2-IL18R1-IL18RAP gene cluster might increase the risk of susceptibility of Graves' disease (GD) and Hashimoto's thyroiditis (HT) in Chinese Han population.
Furthermore, IL-33 injection modulates the innate immune response by polarizing microglia/macrophages toward an antiinflammatory phenotype and reducing the expression of proinflammatory genes, including IL-1beta (show IL1B Antibodies), IL-6 (show IL6 Antibodies), and NLRP3 (show NLRP3 Antibodies), in the cortices of APP (show APP Antibodies)/PS1 (show PSEN1 Antibodies) mice. Collectively, our results demonstrate a potential therapeutic role for IL-33 in AD.
absence of IL-33 has no negative consequences in normal bone homeostasis while high levels of circulating IL-33 contributes to pathological bone loss.
pre-treatment with the ERK1/2 (show MAPK1/3 Antibodies) inhibitor U0126 or anti-IL-33 antibody significantly abolished the ovalbumin (show OVA Antibodies)-induced airway remodeling, increased expressions of IL-33
IL-33 promotes degranulation of bone marrow-derived mast cells and release of cytokines IL-1beta (show IL1B Antibodies), IL-6 (show IL6 Antibodies) and TNF-alpha (show TNF Antibodies).
pulmonary interstitial macrophages may not be a source of IL-33 during Respiratory syncytial virus infection
demonstrate a pathogenic role for IL-33-mediated eosinophilia and activation of Th2 immunity in chronic intestinal inflammation
IL-33 as a novel regulator of neutrophil function in antibacterial infection
IL-33 may be a key molecule operating in eosinophil-mediated fibrosis in high-dose-per fraction irradiated skin.
IL33 (MIM 608678) is a member of the IL1 (see MIM 147760) family that potently drives production of T helper-2 (Th2)-associated cytokines (e.g., IL4\; MIM 147780). IL33 is a ligand for IL33R (IL1RL1\; MIM 601203), an IL1 family receptor that is selectively expressed on Th2 cells and mast cells (summary by Yagami et al., 2010
, DVS27-related protein
, interleukin-1 family member 11
, nuclear factor for high endothelial venules
, nuclear factor from high endothelial venules